Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca 2Q: Soriot's In It For The Long Haul

Executive Summary

AstraZeneca's CEO used the company's second-quarter earnings call to proclaim his commitment to the business just weeks after rumors spread worldwide that he might take up a vacant chief executive role at a rival firm.

You may also be interested in...



2Q Pharma Results Preview: Pfizer, Allergan, Teva, Merck KGaA & Shire

Pfizer will anchor the final week of major biopharma earnings calls, facing the same question as every firm with massive stockpiles of cash: When are you going to spend that money on a transformative M&A deal?

Will Soriot Ditch AstraZeneca In Favor Of Teva… And A $20m Bonus?

Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.

You blew it, Pfizer tells AstraZeneca

Just ahead of the deadline of 5pm 26 May (UK time), Pfizer confirmed the news that everyone had been expecting. Following AstraZeneca's rebuttal of Pfizer's "final" acquisition proposal of 18 May, Pfizer was walking away.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel